{"product_id":"solara-pestle-analysis","title":"Solara Active Pharma Sciences PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock how regulatory shifts, pricing pressures, and innovation trends are reshaping Solara Active Pharma Sciences’ prospects—our concise PESTLE snapshot highlights the critical external forces you need to watch. Purchase the full PESTLE Analysis for a detailed, actionable briefing that investors and strategists rely on to mitigate risk and seize opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernmental Support for API Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Indian government’s PLI scheme for bulk drugs (launched 2020, expanded 2023) allocates ~INR 69.4bn for API and KSMs; Solara Active benefits via incentives for domestic KSM production, improving margins and lowering input costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical China Plus One Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal pharma is diversifying from China; 2023–24 data shows 35% of Western firms actively shifting sourcing, boosting demand for Indian API suppliers. Solara Active Pharma Sciences, with FY2025 API revenues up ~22% YoY and capacity expansions adding 15% output, is a key beneficiary, winning new contracts from US\/EU buyers. Strengthening India-US trade and EU supply-chain pacts further solidify Solara’s market access and order pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Alignment with Global Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical pressure for drug safety in the US and EU forces Indian firms like Solara Active Pharma to meet USFDA and EMA standards; USFDA issued 1,307 drug GMP warning letters globally in 2024, highlighting scrutiny levels relevant to Solara.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDomestic Drug Price Control Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe National Pharmaceutical Pricing Authority caps prices for 384 formulations under the National List of Essential Medicines (as of 2025), a policy that can pressure API margins; Solara’s FY2024 domestic formulations revenue was ~INR 1.2bn, so further inclusion could compress local margins materially.\u003c\/p\u003e\n\u003cp\u003eDespite exports accounting for ~70% of Solara’s revenue in FY2024, expansion of price-controlled lists or new affordability mandates would reduce domestic gross margins and should be factored into revenue forecasts and margin sensitivity analyses.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNPPA controls prices for 384 formulations (2025)\u003c\/li\u003e\n\u003cli\u003eSolara FY2024 domestic formulations revenue ~INR 1.2bn\u003c\/li\u003e\n\u003cli\u003eExports ~70% of FY2024 revenue\u003c\/li\u003e\n\u003cli\u003eNLME expansion risks domestic margin compression\u003c\/li\u003e\n\u003cli\u003ePolicy shifts require stress-testing revenue projections\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade Agreements and Export Incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOngoing FTA talks with the UK and EU could cut tariffs on pharma exports, aiding Solara’s FY2024-25 export push—export revenue rose 18% to INR 1,120 crore in FY2024, making tariff relief material to margins.\u003c\/p\u003e\n\u003cp\u003eSolara uses evolving trade frameworks to enter new markets with lower entry costs; entering EU\/UK could reduce landed costs by an estimated 5–8%, improving competitiveness.\u003c\/p\u003e\n\u003cp\u003eGovernment export incentives like MEIS\/other schemes (support ~5–7% of export value) provide fiscal support to scale capacity in competitive markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 export revenue INR 1,120 crore (up 18%)\u003c\/li\u003e\n\u003cli\u003ePotential landed-cost reduction 5–8% via FTAs\u003c\/li\u003e\n\u003cli\u003eExport incentives contribute ~5–7% of export value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePLI-fueled API boom lifts Solara; export-led growth offsets regulatory \u0026amp; NPPA margin risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePLI incentives (INR 69.4bn) and China diversification lift Solara’s API demand; FY2025 API rev +22% YoY, capacity +15%. US\/EU regulatory scrutiny (USFDA 1,307 GMP letters in 2024) raises compliance costs. NPPA caps 384 drugs (2025) risk domestic margin squeeze; domestic formulations rev ~INR 120cr (FY2024), exports 70% of revenue (FY2024), export rev INR 1,120cr.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePLI allocation\u003c\/td\u003e\n\u003ctd\u003eINR 69.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 API growth\u003c\/td\u003e\n\u003ctd\u003e+22% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity expansion\u003c\/td\u003e\n\u003ctd\u003e+15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSFDA GMP letters (2024)\u003c\/td\u003e\n\u003ctd\u003e1,307\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic formulations rev (FY2024)\u003c\/td\u003e\n\u003ctd\u003eINR 120cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports (% of rev, FY2024)\u003c\/td\u003e\n\u003ctd\u003e70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport rev (FY2024)\u003c\/td\u003e\n\u003ctd\u003eINR 1,120cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors—Political, Economic, Social, Technological, Environmental, and Legal—uniquely impact Solara Active Pharma Sciences, with each section supported by current data and trends to highlight risks and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise PESTLE snapshot of Solara Active Pharma Sciences that’s visually segmented for quick reading, easily dropped into presentations, shared across teams, and annotated with region- or business-specific notes to support risk discussions and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Rate Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a major exporter, Solara Active Pharma Sciences sees revenue sensitive to INR\/USD and INR\/EUR moves; a 5% rupee depreciation in 2024 lifted export competitiveness but also magnified local-currency revenue volatility. While a weaker rupee can boost reported earnings, it raised 2024 imported specialty-chemical costs by roughly 6–8%, squeezing gross margins. The company reports using dynamic hedging and forward contracts covering about 60–75% of foreign-currency exposure to stabilize cash flow and earnings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment and Debt Servicing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSolara Active Pharma Sciences holds net debt of about INR 1,150 crore as of FY2025, so rising RBI policy rates (repo 6.50% in Dec 2025) would raise interest expense and compress EBITDA margins. Higher borrowing costs could cut funds available for R\u0026amp;D and capacity expansion, given FY2025 interest coverage near 3.2x. Investors track the debt-to-equity ~0.9x and refinancing risk if market rates stay elevated, affecting long-term solvency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Inflation and Input Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal inflation elevated energy and logistics costs by about 8–10% in 2023–24, and solvent prices rose up to 15%, directly inflating COGS for API makers like Solara Active Pharma Sciences.\u003c\/p\u003e\n\u003cp\u003eWith long-term contracts limiting price adjustments, Solara risks margin compression or share loss to low-cost Asian competitors unless it negotiates pass-through clauses or hedges inputs.\u003c\/p\u003e\n\u003cp\u003eEfficient procurement, bulk sourcing and process optimization—which reduced feedstock spend by 5–7% in industry peers in 2024—are critical to preserve margins during sustained inflation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth of the Generic Drug Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe global generic drug market reached about USD 380 billion in 2024 and is projected to grow at ~6–7% CAGR through 2029, fueling demand for Solara’s APIs as payers push affordable care.\u003c\/p\u003e\n\u003cp\u003eBudget pressures in OECD countries accelerate substitution to generics, creating stable off-take for high-quality active ingredients that Solara supplies.\u003c\/p\u003e\n\u003cp\u003eSolara is expanding complex-API offerings—higher value-added products that typically command 15–30% gross margin premiums—supporting revenue diversification and margin enhancement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal generics ~USD 380B (2024); 6–7% CAGR to 2029\u003c\/li\u003e\n\u003cli\u003eOECD budget constraints → rising generic uptake\u003c\/li\u003e\n\u003cli\u003eComplex APIs command 15–30% higher gross margins\u003c\/li\u003e\n\u003cli\u003eSolara expanding complex-API portfolio to capture demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Investment in R and D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTax credits and R\u0026amp;D incentives in India and export markets (estimated 15–20% effective relief in select jurisdictions) push Solara Active Pharma Sciences to scale capex in innovative manufacturing, lowering net project costs and boosting ROI.\u003c\/p\u003e\n\u003cp\u003eCapex on process chemistry and green synthesis reduces per-unit costs versus smaller CDMOs; recent industry benchmarks show 10–25% margin improvement from process optimization.\u003c\/p\u003e\n\u003cp\u003eSolara’s sustained R\u0026amp;D funding capacity—backed by ~INR 500–1,000 crore sectoral investments seen in 2024–25—underpins its long-term economic moat in complex APIs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTax credits ~15–20% enhance R\u0026amp;D ROI\u003c\/li\u003e\n\u003cli\u003eProcess innovation yields 10–25% margin gains\u003c\/li\u003e\n\u003cli\u003eSustained sector capex ~INR 500–1,000 crore (2024–25)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRupee dip boosts exports; hedges limit FX pain—net debt INR1,150cr, generics growth ahead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRupee moves (5% 2024 depreciation) boost export competitiveness but raised imported-chem costs ~6–8%; hedging covers 60–75% FX exposure. Net debt ~INR1,150cr (FY25) with interest coverage ~3.2x; repo ~6.50% (Dec 2025) risks higher interest expense. Global generics ~USD380B (2024), 6–7% CAGR to 2029; complex-API premiums 15–30%, tax\/R\u0026amp;D relief ~15–20%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (FY25)\u003c\/td\u003e\n\u003ctd\u003eINR1,150cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX hedge\u003c\/td\u003e\n\u003ctd\u003e60–75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal generics\u003c\/td\u003e\n\u003ctd\u003eUSD380B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAGR to 2029\u003c\/td\u003e\n\u003ctd\u003e6–7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eSolara Active Pharma Sciences PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Solara Active Pharma Sciences PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751265612153,"sku":"solara-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/solara-pestle-analysis.png?v=1772229479","url":"https:\/\/growthsharematrix.com\/products\/solara-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}